🗒️2024 ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment 💊

@Y_ECCO_IBD
 #IBD #MedEd #GITwitter #MedTwitter

1️⃣4️⃣ Statements and 6️⃣Practice points

1️⃣ 5-ASA is not recommended🚫for the induction or maintenance therapy in CD➡️consistent lack of evidence.

🧵👇

@Y_ECCO_IBD 2️⃣ Budesonide💊 is recommended for inducing clinical remission in patients with active, mild-to-moderate CD limited to the ileum / ascending colon🎯

👉Additionally, systemic corticosteroids are suggested for induction therapy in patients with active, moderate-to-severe CD💉

📚 ECCO Guidelines on Extraintestinal Manifestations in IBD 🏥:

A thread 🧵
32 Statements by @Y_ECCO_IBD summarized 👇

@my_ueg @JCC_IBD @manu_barreiro @TrianaLobaton @GianlucaPellino

#Medtwitter #GITwitter #MedEd #IBD @Y_ECCO_IBD @my_ueg @JCC_IBD @manu_barreiro @TrianaLobaton @GianlucaPellino 🔍 S1: 🚨 Thrombotic events are more than 2x as frequent in patients with IBD than in the general population, with similar prevalence in ulcerative colitis and Crohn’s disease 🦠. The most important risk factors? Active disease, hospitalization, and surgery 🏥.

🔦Endoscopic Diagnosis & Management of Esophagogastric Variceal Hemorrhage
🗒️ESGEGuidelines2022

16 Keys:

1⃣Pts w compensated advanced CLD & >10mmHg portalHT➡️NSBB (carvedilol) therapy💊

@ESGE_news #LiverTwitter #MedEd #GITwitter #MedTwitter @ASGEendoscopy @endoscopyjrnl
🧵👇 2⃣ Patients unable to receive NSBB therapy with a screening upper endoscopy 🔦that demonstrates high risk esophageal varices ➡️ endoscopic band ligation (EBL). Repeat after 2-4 weeks until eradication
🕵️‍♂️Surveillance every 6 months in the first year